Two analyst initiations: Roth Capital (Buy, $3.50 PT) and Leerink (Outperform, $4 PT)
A Nature Methods paper validating their Voyager platform for large-scale proteoform analysis, with a goal of \~20 proteoform assays by mid-2028
Volume way above average, plus an amended 13D/A from a major holder
**Why I think there's real potential**
Proteomics is still far behind genomics in what we can actually measure. If Voyager works at scale, it could matter a lot for drug discovery and diagnostics, especially in neuro and oncology. A peer-reviewed paper is more than most small caps can show.
**Risks**
Almost no revenue (\~$190k TTM) against a \~$56M yearly net loss
New ATM offering set up in September, so dilution into this rally is possible
Market cap only \~$250M, so it moves hard both ways
**Discussion**
Is this the start of Wall Street re-rating the company, or a typical biotech spike that fades once the ATM gets used? Anyone following proteomics have a view on how Voyager compares to competitors?